| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1111/LIV.13477 |
| P698 | PubMed publication ID | 28517369 |
| P50 | author | Sammy Saab | Q88094221 |
| P2093 | author name string | Melissa Jimenez | |
| Gina Choi | |||
| Duminda Suraweera | |||
| Harman Rahal | |||
| Matthew Viramontes | |||
| P2860 | cites work | Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review | Q27024273 |
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Fenofibrate in primary biliary cirrhosis: a pilot study. | Q33912957 | ||
| 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. | Q34143282 | ||
| Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. | Q34453425 | ||
| Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis | Q37760788 | ||
| Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis | Q37855976 | ||
| Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis | Q37963978 | ||
| Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid | Q39293482 | ||
| Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score | Q39584105 | ||
| The true impact of fatigue in primary biliary cirrhosis: a population study | Q40643274 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid | Q43013514 | ||
| Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone | Q43086793 | ||
| Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study | Q43471968 | ||
| Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid | Q43483632 | ||
| Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid | Q43893454 | ||
| Fenofibrate treatment in patients with primary biliary cirrhosis | Q44110727 | ||
| A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis | Q45040478 | ||
| Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid | Q46126105 | ||
| Methotrexate induced mitochondrial injury and cytochrome c release in rat liver hepatocytes | Q46403632 | ||
| Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis | Q46408092 | ||
| The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study | Q46614923 | ||
| Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis | Q46775425 | ||
| Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid | Q51636366 | ||
| High-dose inhaled budesonide may substitute for oral therapy after an acute asthma attack. | Q53843390 | ||
| Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. | Q54032405 | ||
| Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. | Q54040784 | ||
| EASL Clinical Practice Guidelines: management of cholestatic liver diseases. | Q55051951 | ||
| Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid | Q55174800 | ||
| Primary biliary cirrhosis | Q56428273 | ||
| P433 | issue | 12 | |
| P921 | main subject | ascending cholangitis | Q603644 |
| systematic review | Q1504425 | ||
| P304 | page(s) | 1877-1886 | |
| P577 | publication date | 2017-06-14 | |
| P1433 | published in | Liver International | Q15765078 |
| P1476 | title | Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review | |
| P478 | volume | 37 |
| Q64077115 | A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist |
| Q92892621 | Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases |
| Q57114658 | Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Utilization |
| Q55190939 | Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis. |
Search more.